Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Both are peptide therapeutics rather than small molecules
Enter the dose you want to inject
Harnessing nanotechnology for cancer treatment
Glucagon-like peptide-1 (GLP-1) agonist therapies are increasingly being used for type 2 diabetes and obesity, but evidence now shows they also reduce inflammation across multiple organs through mechanisms related and unrelated to weight-loss-driven metabolic improvements
Furthermore, the secular trends of causes of mortality in patients with diabetes shows an increase for neurodegenerative causes (e.g., dementia) and liver diseases [65]
